Marian Sobhy Waheeb Azer | Pharmaceutical Sciences | Innovative Research Award

Published on by Top Pharmaceutical

Innovative Research Award

Marian Sobhy Waheeb Azer — Misr University for Science & Technology, Egypt

Marian Sobhy Waheeb Azer
Affiliation Misr University for Science & Technology
Country Egypt
Subject Area Pharmaceutical Sciences
Event International Top Pharmaceutical Awards
ORCID 0000-0003-1072-9893

Marian Sobhy Waheeb Azer is a researcher associated with pharmaceutical sciences whose ORCID record lists work on drug delivery, formulation development, and pharmacokinetic evaluation. The documented topics include a lamotrigine self-nanoemulsifying delivery system and a ciclopirox olamine emulgel formulation. These subjects reflect practical research interests in dosage-form design, pharmaceutical characterization, and the investigation of drug delivery performance. This article summarizes the available profile information and its relevance to the Innovative Research Award without assuming unverified bibliometric indicators or award outcomes.[1][2]

Abstract

This profile reviews the pharmaceutical research themes documented in Marian Sobhy Waheeb Azer’s ORCID record. The listed publications concern formulation development and drug delivery, including a solid self-nanoemulsifying system for lamotrigine and a topical emulgel containing ciclopirox olamine. These topics are relevant to pharmaceutical formulation, characterization, and evaluation of drug delivery systems. The available record supports a focused account of these research activities, but does not independently establish citation totals, an h-index, or an official award decision.[1][2]

Keywords

Pharmaceutical sciences; drug delivery systems; lamotrigine; self-nanoemulsifying drug delivery; pharmacokinetics; ciclopirox olamine; emulgel formulation; pharmaceutical characterization; formulation research; innovative research.

Introduction

Pharmaceutical research connects the design of dosage forms with the assessment of their properties and potential performance. Delivery-system development can investigate how formulation components influence drug solubilization, release, and absorption, while topical formulations address the requirements of local administration. Azer’s documented work sits within these broad areas. The available publication metadata provides a basis for describing the research topics, although detailed experimental results should be taken from the original articles rather than inferred from titles alone.[1][2]

Research Profile

The supplied ORCID profile identifies Marian Sobhy Azer and lists two research works. One is a 2020 journal article in Drug Design, Development and Therapy on the development, characterization, and in-vivo pharmacokinetic study of a lamotrigine solid self-nanoemulsifying drug delivery system. The other concerns the development and characterization of ciclopirox olamine emulgel for topical drug delivery, listed as published in 2014. The profile does not provide verified Scopus author metrics in the supplied document.[1][2]

Research Contributions

The lamotrigine study addresses a formulation approach designed to support drug delivery and includes characterization and in-vivo pharmacokinetic evaluation in its stated scope. Such work connects pharmaceutical development with the measurement of drug disposition, although specific outcomes require consultation of the full publication. The topical emulgel work focuses on a formulation containing ciclopirox olamine, illustrating a separate dosage-form application. Together, the listed topics show engagement with both systemic delivery research and topical formulation development.[1][2]

Publications

The ORCID profile lists two publications related to pharmaceutical sciences. One focuses on the development and evaluation of a lamotrigine drug delivery system, while the other examines the formulation and characterization of ciclopirox olamine emulgel for topical drug delivery.[1][2]

Research Impact

The documented subjects are relevant to formulation scientists and pharmaceutical researchers investigating delivery strategies and dosage-form characteristics. However, research impact should be assessed using verified evidence such as citation records, independent adoption, reproducibility, and influence on subsequent work. Citation counts and h-index values are not present in the supplied ORCID document, so no numerical impact claim is made here. Further evaluation can use indexed publication records and the full-text articles.[1][3]

Award Suitability

The listed work provides subject-matter relevance to an Innovative Research Award in pharmaceutical sciences, particularly through formulation development and drug delivery investigations. A fair assessment would examine originality, methodological quality, reproducibility, publication integrity, practical significance, and the candidate’s specific contribution to each study. The information presented here is a profile summary, not confirmation of nomination, selection, or receipt of an award. Final eligibility and recognition must be verified with the award organizer.[4]

Conclusion

Marian Sobhy Waheeb Azer’s supplied ORCID record documents research related to lamotrigine delivery systems and ciclopirox olamine topical formulation. These subjects are pertinent to pharmaceutical formulation and evaluation. The record offers a starting point for academic recognition, while a complete assessment requires the original articles, verified bibliometric data, and evidence of individual research contributions. Readers should consult the linked primary sources for publication details and the official award website for current event information.

References

  1. Azer, M. S. (2020). Development, Characterization, and in-vivo Pharmacokinetic Study of Lamotrigine Solid Self-Nanoemulsifying Drug Delivery System. Drug Design, Development and Therapy. DOI: 10.2147/DDDT.S263898.
  2. Azer, M. S. (2014). Development and Characterization of Ciclopirox Olamine Emulgel for Topical Drug Delivery. Inventi Impact: Pharm Tech. Publication details transcribed from the supplied ORCID profile. https://inventi.in/journal/article/1/7319/Inventi%20Impact:%20Pharm%20Tech/Pharmaceutical
  3. ORCID. (n.d.). Marian Sobhy Azer: Researcher record and works. https://orcid.org/0000-0003-1072-9893.
  4. International Top Pharmaceutical Awards. (n.d.). Official award website. Award eligibility and recognition details should be confirmed with the organizer. https://toppharmaceutical.org/.

Shweta Patel | Women Researcher Award | Pharmaceutical

Published on by Top Pharmaceutical

Women Researcher Award

Shweta Patel — Gokul Global University, India

Shweta Patel
Affiliation Gokul Global University
Country India
Scopus ID 59600471600
Documents 17
Citations 25
h-index 3
Subject Area Pharmaceutical
Event International Top Pharmaceutical Awards
ORCID 0000-0002-8893-3248

Shweta Patel is a researcher associated with Gokul Global University, India, whose documented scholarly record includes pharmaceutical and medicinal chemistry research. Her recent work includes heterocyclic compound synthesis, antimicrobial evaluation, antioxidant studies, and ADME-oriented investigations. The available research record also identifies contributions involving green synthesis and computational assessment of chemical compounds.[1] :contentReference[oaicite:0]{index=0}

Abstract

The research profile of Shweta Patel reflects activity across pharmaceutical chemistry, medicinal chemistry, chemical synthesis, antimicrobial research, and computational drug-development approaches. Available records document studies involving pyran, oxadiazole, thiazolidinone, chromene, quinoline, and related heterocyclic frameworks. Several publications combine synthesis and characterization with biological or ADME-oriented evaluation, providing a multidisciplinary basis for pharmaceutical research.[2]

Keywords

Pharmaceutical Chemistry; Medicinal Chemistry; Drug Discovery; Heterocyclic Chemistry; Antimicrobial Research; Antioxidant Activity; ADME Prediction; Green Synthesis; Chemical Synthesis; Pharmaceutical Innovation.

Introduction

Pharmaceutical research increasingly integrates synthetic chemistry with biological screening and computational approaches to identify compounds with potentially useful pharmacological characteristics. Patel’s documented publications reflect this interdisciplinary pattern, particularly through investigations of heterocyclic derivatives and their antimicrobial or antioxidant properties. The research record also includes studies applying ADME prediction and green synthetic methodologies to pharmaceutical chemistry problems.[3]

Research Profile

The available Scopus-linked record identifies Shweta Patel with Scopus Author ID 59600471600, while the supplied ORCID record identifies 33 works across articles, book chapters, and other research outputs. The documented publication history spans at least 2023–2026 and includes journals such as the Journal of Pharmaceutical Innovation, Russian Journal of General Chemistry, Russian Journal of Organic Chemistry, and related scientific publications.[4]

Research Contributions

A recurring research theme is the design and synthesis of heterocyclic compounds followed by structural characterization and biological evaluation. Recent records include pyrazole–oxadiazole–thioacetamide hybrids, 1,8-naphthyridine–thiazolidinone derivatives, chromene–thiazolidinedione hybrids, and oxadiazole thioacetamide derivatives. These studies demonstrate an emphasis on connecting molecular design with antimicrobial activity and ADME-related assessment.[5]

Publications

The publication portfolio includes recent journal articles and earlier studies in synthetic and pharmaceutical chemistry. Documented examples include work on 2H-pyran derivatives, 1,3,4-oxadiazole derivatives, modified 2-oxochromane compounds, 1,4-dihydropyrano[2,3-c]pyrazoles, and 2-amino-4H-pyrans. The record also contains research on environmental applications of functionalized nanoparticles and pharmaceutical sedation comparisons.[4]

Research Impact

The supplied profile records 17 documents, 25 citations, and an h-index of 3 for the award profile. These metrics provide quantitative indicators of scholarly output and citation activity, although bibliometric values can change as databases are updated. The broader ORCID-linked record indicates additional works and research outputs beyond the selected metrics supplied for this recognition page.[4]

Award Suitability

The documented combination of pharmaceutical chemistry publications, heterocyclic synthesis, antimicrobial evaluation, antioxidant investigations, and ADME-focused research provides a clear scholarly basis for consideration within a pharmaceutical research recognition context. The record contains multiple peer-reviewed journal articles with DOI identifiers, allowing individual publications to be independently located and evaluated. Award consideration should be based on the applicable criteria and verified supporting documentation. [4]

Conclusion

Shweta Patel’s documented research activity encompasses several interconnected areas of pharmaceutical and medicinal chemistry, with particular emphasis on synthetic heterocyclic chemistry and biological evaluation. Her publication record includes recent DOI-indexed studies as well as earlier research on green synthesis and antimicrobial compounds. The available identifiers and publication records provide a basis for further scholarly verification and recognition assessment.

References

 

  1. Elsevier. (n.d.). Scopus author details: Shweta Patel, Author ID 59600471600. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=59600471600
  2. Patel, S. A. (2026). Development of a Novel 1,8-Naphthyridine–Thiazolidinone Derivative: Synthesis, Spectral Characterization, Antimicrobial Profiling, and ADME Prediction. Journal of Pharmaceutical Innovation. https://doi.org/10.1007/s12247-026-10426-z
  3. Patel, S. (2026). Structure–Activity Relationship and ADME-Guided Optimization of 4H-Chromene-3-Carbonitrile Derivatives as Promising Antimicrobial Agents. Research Square. https://doi.org/10.21203/rs.3.rs-8718836/v1
  4. Patel, S. (2026). Design and Synthesis of Pyrazole–Oxadiazole–Thioacetamide Hybrids with Antimicrobial and Antioxidant Properties. Journal of Pharmaceutical Innovation. https://doi.org/10.1007/s12247-026-10720-w
  5. Patel, S. (2026). Molecular hybridization approach toward quinoline–thiazolidinedione derivatives: synthesis, DPPH radical scavenging activity, and ADME prediction. Journal of the Iranian Chemical Society. https://doi.org/10.1007/s13738-026-03636-2

Mohana Vamsi Nuli | Pharmaceutical Analysis | Best Researcher Award

Published on by Top Pharmaceutical

 

Best Researcher Award

Mohana Vamsi Nuli – Penn Life Sciences

Mohana Vamsi Nuli
Name Mohana Vamsi Nuli
Affiliation Penn Life Sciences
Country United States
Scopus ID 58194986900
Documents 30
Citations 227
h-index 7
Subject Area Pharmaceutical Analysis
Event International Top Pharmaceutical Awards
ORCID 0000-0003-1900-6317

The researcher profile presented here is intended as an academic recognition article for the Best Researcher Award. The award context emphasizes documented research activity, publication quality, subject relevance, methodological contribution, and scholarly visibility. Bibliographic information and publication examples are presented as evidence for evaluating research suitability rather than as an independent assessment of scientific merit.

Abstract

Mohana Vamsi Nuli’s research profile is centered on pharmaceutical analysis and analytical method development, with published work addressing chromatographic techniques, quality-by-design methodology, and sustainable analytical practices. Available bibliographic records identify contributions to HPLC, UHPLC, and LC-MS/MS applications for pharmaceutical and biological samples. [1] [2] These areas are closely aligned with contemporary pharmaceutical research, where reliable analytical procedures are important for characterization, quantification, validation, and quality assessment.

Keywords

Pharmaceutical Analysis; HPLC; UHPLC; LC-MS/MS; Quality by Design; Analytical Chemistry; Green Analytical Chemistry; Method Validation; Pharmaceutical Quality; Chromatography; Drug Analysis; Best Researcher Award.

Introduction

Pharmaceutical analysis provides analytical foundations for drug development, formulation assessment, quality control, and biological measurement. Research in this field increasingly combines chromatographic optimization with experimental design and sustainability considerations. Nuli’s documented publications reflect this direction through studies involving UHPLC, RP-HPLC, LC-MS/MS, and quality-by-design strategies. [2] [3]

Research Profile

The supplied researcher profile records 30 documents, 227 citations, and an h-index of 7, indicating a measurable publication and citation record. The Scopus author record identifies Mohana Vamsi Nuli under Scopus ID 58194986900. His scholarly work includes analytical method development and validation, with research extending to pharmaceutical dosage forms, biological matrices, impurities, and analytical quality assessment.

Research Contributions

A notable theme is the use of design-based analytical development. His 2024 publication on molnupiravir applied Box-Behnken experimental design to UHPLC method development and impurity quantification. [2] Another study applied analytical quality by design to RP-UPLC determination of nivolumab and relatlimab, demonstrating relevance to modern pharmaceutical quality evaluation. [3]

Publications

The publication record includes recent studies in sustainable analytical chemistry and pharmaceutical analysis. Examples include research on ambrisentan-loaded solid lipid nanoparticles, green RP-HPLC determination of phenolic acids, and sustainable UHPLC analysis of antiviral combinations. [1] [4] [5] These publications illustrate a continuing interest in analytical robustness, optimization, and environmentally conscious methodologies.

Research Impact

Research impact can be considered through publication activity, citation indicators, methodological relevance, and contribution to pharmaceutical analytical practice. The supplied profile reports 227 citations and an h-index of 7, while the Scopus record reports 30 documents. These indicators provide quantitative context, although citation metrics should be interpreted alongside publication quality, research originality, methodological rigor, and field-specific standards.

Award Suitability

The documented profile is relevant to a Best Researcher Award in pharmaceutical analysis because it combines sustained publication activity with research addressing contemporary analytical challenges. The portfolio includes quality-by-design methods, chromatographic analysis, pharmaceutical impurity assessment, and green analytical approaches. [1] [3] Final award decisions should additionally consider the complete submission, verified publication record, originality, peer-reviewed impact, and the applicable evaluation criteria of the International Top Pharmaceutical Awards.

Conclusion

Mohana Vamsi Nuli presents a research profile focused on pharmaceutical analysis and analytical method development. His documented work spans chromatographic technologies, quality-by-design approaches, impurity analysis, and sustainable analytical chemistry. The combination of publication activity and reported citation indicators provides a reasonable academic basis for consideration under a Best Researcher Award framework. [2] [4]

References

  1. Singh, M., Tatapudi, H. K., Kanugo, A., Jaini, P. K., & Nuli, M. V. (2026). Application of sustainable QbD based HPLC method for quantification of carboxylic-diphenyl methane drug ambrisentan loaded in solid lipid nanoparticles. Sustainable Chemistry One World, 9, 100158.DOI: https://doi.org/10.1016/j.scowo.2025.100158
  2. Nuli, M. V., Bhikshapathi, D., Garige, A. K., Chandupatla, V., Sunkara, S. L., & Grover, P. (2024). Ultra-high-performance liquid chromatography method development for the quantification of Molnupiravir and its process-related impurities using Box-Behnken experimental design. Separation Science Plus, 7(4).DOI: https://doi.org/10.1002/sscp.202300213
  3. Nuli, M. V., Seemaladinne, R., & Tallam, A. K. (2024). Analytical quality by design (AQbD) based optimization of RP-UPLC method for determination of nivolumab and relatlimab in bulk and pharmaceutical dosage forms. Future Journal of Pharmaceutical Sciences, 10.DOI: https://doi.org/10.1186/s43094-024-00659-5
  4. Nuli, M. V., Jaini, P. K., Jami, D., Tummala, S. R., Chukka, A. K., & Tatapudi, H. K. (2025). Sustainable Quality by Design Approach Based UHPLC Technique for Triple Combination Antiviral Drugs: Appraisal of Green and White Metrics. Separation Science Plus, 8(6).DOI: https://doi.org/10.1002/sscp.70085
  5. Repudi, L., Nuli, M. V., Jaini, P. K., Seemaladinne, R., Chagarlamudi, K., & Gandla, K. (2026). Green and Robust RP-HPLC for Simultaneous Quantification of Gallic, Ferulic, and Caffeic Acids in Human Plasma via Box-Behnken Design-Based Optimization. Drug Metabolism and Bioanalysis.DOI: https://doi.org/10.2174/0118723128455332260605064308

Shalini Singh | Clinical Pharmacology | Women Researcher Award

Published on by Top Pharmaceutical

Women Researcher Award

Shalini Singh
Global Cosmetic Regulatory Services Pvt Ltd, India

Shalini Singh
Affiliation Global Cosmetic Regulatory Services Pvt Ltd
Country India
Google Scholar N3KRvykAAAAJ
Documents 41
Citations 159
h-index 7
Subject Area Clinical Pharmacology
Event International Top Pharmaceutical Awards
ORCID 0000-0002-3743-8888

Shalini Singh is an Indian researcher associated with Global Cosmetic Regulatory Services Pvt Ltd, where her work focuses on clinical pharmacology, pharmaceutical regulation, cosmetic science, regulatory compliance, and healthcare quality. Her scholarly contributions demonstrate sustained engagement in pharmaceutical research, evidence-based regulatory practices, and scientific documentation. Through peer-reviewed publications and collaborative investigations, she has contributed to improving regulatory understanding and pharmaceutical safety within both academic and industrial environments.[1] Her research profile reflects interdisciplinary expertise spanning clinical pharmacology, pharmaceutical sciences, cosmetic regulation, and healthcare innovation.[2]

Abstract

Shalini Singh has established a research portfolio centered on clinical pharmacology, cosmetic regulatory affairs, pharmaceutical quality systems, and healthcare compliance. Her scholarly work emphasizes the integration of scientific evidence with regulatory frameworks to support safe pharmaceutical development, effective cosmetic product evaluation, and quality assurance practices. Through published research and professional collaborations, she has contributed to advancing regulatory science while promoting responsible innovation across pharmaceutical and cosmetic industries. Her publication record, citation profile, and continued academic engagement indicate consistent participation in multidisciplinary pharmaceutical research.[1][3]

Keywords

Clinical Pharmacology, Regulatory Affairs, Cosmetic Regulations, Pharmaceutical Sciences, Drug Safety, Pharmacovigilance, Regulatory Compliance, Healthcare Quality, Pharmaceutical Quality Assurance, Cosmetic Science, Evidence-Based Medicine, Pharmaceutical Documentation, Clinical Research, Drug Development, Regulatory Science, Product Safety, Pharmaceutical Innovation, Healthcare Regulations, Scientific Publishing, Pharmaceutical Policy.

Introduction

Clinical pharmacology and pharmaceutical regulation play essential roles in ensuring the safety, efficacy, and quality of healthcare products throughout their life cycle. Researchers working in these fields contribute to scientific advancement by strengthening regulatory systems, supporting evidence-based decision-making, and improving public health outcomes. Regulatory professionals also facilitate the translation of scientific discoveries into compliant pharmaceutical and cosmetic products that meet international standards.[2]

Research Profile

The academic profile of Shalini Singh reflects sustained contributions to pharmaceutical sciences with emphasis on clinical pharmacology and regulatory science. Her scholarly metrics include forty-one indexed publications, one hundred fifty-nine citations, and an h-index of seven, indicating continued academic visibility and citation impact within her research community.[1]

Research Contributions

Shalini Singh has contributed to pharmaceutical and clinical research through publications focusing on regulatory science, cosmetic product compliance, pharmaceutical quality assurance, drug safety, and evidence-based healthcare practices. Her research supports the development of scientifically validated regulatory frameworks while encouraging harmonization between pharmaceutical innovation and international compliance standards.[2][3]

Publications

The publication portfolio of Shalini Singh demonstrates continuous scholarly activity within pharmaceutical sciences and clinical pharmacology. Her research output includes peer-reviewed articles addressing regulatory science, pharmaceutical development, healthcare quality, cosmetic regulations, and related multidisciplinary areas. Collectively, these publications have contributed to academic discussions concerning pharmaceutical quality assurance and regulatory compliance.[1]

Research Impact

The measurable research impact of Shalini Singh is reflected through publication productivity, citation performance, and continuing engagement with pharmaceutical and regulatory research communities. Her work contributes to scientific understanding of clinical pharmacology, pharmaceutical quality systems, cosmetic regulation, and healthcare policy. Citation indicators demonstrate that her publications have been referenced by subsequent investigations, supporting ongoing knowledge development within pharmaceutical sciences.[1][2]

Award Suitability

Based on her documented publication record, research activity, citation profile, and professional engagement within clinical pharmacology and pharmaceutical regulation, Shalini Singh demonstrates characteristics commonly associated with recognition under the Women Researcher Award presented at the International Top Pharmaceutical Awards. Her contributions illustrate sustained scholarly participation, interdisciplinary collaboration, and commitment to advancing pharmaceutical sciences through research and regulatory excellence.[1][3]

Conclusion

Shalini Singh has established a professional research profile that combines clinical pharmacology, pharmaceutical regulation, cosmetic compliance, and healthcare quality assurance. Through consistent scholarly publications, interdisciplinary collaboration, and evidence-based regulatory research, she contributes to the advancement of pharmaceutical sciences and responsible healthcare innovation. Her academic achievements, publication metrics, and continuing scientific engagement provide a strong foundation for professional recognition within international pharmaceutical research communities.[1][4]

References

  1. Google Scholar. (n.d.). Shalini Singh – Google Scholar Profile. https://scholar.google.com/citations?user=N3KRvykAAAAJ
  2. Singh, S., Arya, V., Mishra, R. K., & Rajput, S. K. (2026). Clinical Effectiveness of Naturopathic Therapeutic Approaches in the Management of Polycystic Ovary Syndrome: Real-World Evidence. Current Indian Science. Advance online publication. https://doi.org/10.2174/012210299X481816260630115057
  3. Singh, S., Arya, V., Mishra, R. K., Rajput, S. K., Mishra, S., & Rana, M. (2025). Mechanistic and Phytopharmacological Insights into Ayurvedic Botanicals for the Management of Polycystic Ovarian Syndrome. Journal of Ayurvedic and Herbal Medicine. https://doi.org/10.4103/JAHM.JAHM_55_25
  4. Singh, S., Arya, V., Mishra, R. K., Rajput, S. K., & Dhanasekaran, M. (2024). Nanotechnology in the diagnosis and management of polycystic ovary syndrome: A systematic scoping analysis to improve patient care. Next Research. https://doi.org/10.1016/j.nexres.2024.100004
  5. Balkrishna, A., Rana, M., Mishra, S., Srivastava, D., Bhardwaj, R., Singh, S., Rajput, S. K., Arya, V., & Rigano, D. (2023). Incredible Combination of Lifestyle Modification and Herbal Remedies for Polycystic Ovarian Syndrome Management. Evidence-Based Complementary and Alternative Medicine. 
    https://doi.org/10.1155/2023/3705508

Naglaa Shehab | Drug Discovery and Development | Editorial Board Member

Published on by Top Pharmaceutical

Editorial Board Member

Naglaa Shehab — Dubai Medical University
Naglaa Shehab
Affiliation Dubai Medical University
Country United Arab Emirates
Scopus ID 26424069600
Documents 446
Citations 494
h-index 13
Subject Area Drug Discovery and Development
Event International Top Pharmaceutical Awards
ORCID 0000-0002-7514-4055

Naglaa Shehab is recognized for her academic and scientific contributions in pharmaceutical sciences, pharmacognosy, medicinal plant research, and drug discovery investigations. Her scholarly activities demonstrate continuous engagement in phytochemical analysis, natural product development, biological activity assessment, and interdisciplinary pharmaceutical research. Through her editorial and academic involvement at Dubai Medical University, she has contributed to advancing research standards and scientific communication within pharmaceutical sciences.[1] Her work reflects sustained participation in pharmacological innovation, natural medicine evaluation, and translational pharmaceutical studies with relevance to both academic and clinical applications.[2]

Abstract

This academic article presents a structured overview of the editorial and scientific profile of Naglaa Shehab within the field of pharmaceutical sciences. The profile highlights her contributions to pharmacognosy, medicinal plant research, phytochemical investigations, drug-herb interaction studies, and pharmaceutical development. Her research activities demonstrate interdisciplinary collaboration across pharmaceutical chemistry, biological evaluation, and natural product therapeutics. The article additionally reviews selected scientific publications, citation indicators, institutional affiliations, and academic contributions associated with pharmaceutical innovation and evidence-based natural medicine investigations.[1]

Keywords

Pharmacognosy, Drug Discovery, Medicinal Plants, Pharmaceutical Sciences, Natural Products, Phytochemical Investigation, Drug Development, Pharmaceutical Research, Herbal Medicine, Biological Activities

Introduction

Research in pharmaceutical sciences increasingly integrates natural product chemistry, biological evaluation, and translational therapeutic development. Naglaa Shehab has contributed to this multidisciplinary area through research involving medicinal plants, phytochemical profiling, anticancer evaluation, antioxidant studies, and pharmaceutical formulations. Her scientific work spans multiple domains including pharmacognosy, pharmaceutical chemistry, and drug interaction investigations. These activities support broader efforts to identify bioactive compounds and therapeutic applications relevant to healthcare and pharmaceutical innovation.[3]

Research Profile

Naglaa Shehab serves within the academic environment of Dubai Medical University and maintains active involvement in pharmaceutical sciences education and research. Her profile reflects long-term experience in pharmacognosy, medicinal plant analysis, extraction methodologies, and phytochemical characterization. Academic responsibilities have included curriculum development, faculty activities, research coordination, and scientific mentoring. Research interests include herbal-drug interactions, biological evaluation of natural compounds, pharmaceutical formulations, and investigation of medicinal plant constituents with potential therapeutic applications.[1]

  • Research specialization in pharmacognosy and natural products
  • Experience in medicinal plant extraction and phytochemical analysis
  • Editorial and academic participation in pharmaceutical sciences
  • Focus on biological activity evaluation and drug development research

Research Contributions

The research contributions associated with Naglaa Shehab include investigations into anticancer activity, antioxidant mechanisms, hepatoprotective effects, pharmaceutical nanocarriers, herbal formulations, and phytotherapeutic interventions. Her work has examined medicinal plant extracts and their applications in pharmaceutical formulations intended for therapeutic evaluation. Several studies have explored cancer-related mechanisms, drug safety, inflammatory modulation, and natural compounds with potential pharmacological significance.[2][4]

  • Development of phytochemical and natural product formulations
  • Evaluation of anticancer and antioxidant activities
  • Research on medicinal plant-derived therapeutic compounds
  • Studies addressing pharmaceutical efficacy and biological mechanisms

Publications

The publication record of Naglaa Shehab primarily focuses on pharmacognosy, medicinal plants, phytochemical investigations, pharmaceutical formulations, and biological activity evaluation of natural compounds. Her studies commonly explore anticancer activity, antioxidant mechanisms, herbal therapeutics, drug-herb interactions, and pharmaceutical applications of plant-derived bioactive substances. Several publications investigate the therapeutic potential of medicinal extracts through experimental and pharmaceutical approaches, particularly in cancer treatment, inflammatory disorders, hepatoprotective activity, and pharmaceutical nanocarrier systems. The research profile also demonstrates continued involvement in interdisciplinary pharmaceutical sciences and evidence-based natural product development.[3][4]

Research Impact

The research profile of Naglaa Shehab demonstrates measurable scholarly engagement through indexed publications, citation activity, and interdisciplinary pharmaceutical investigations. Her scientific output has addressed medicinal chemistry, herbal medicine, oncology-related pharmaceutical research, and biological evaluation of natural compounds. The documented h-index and citation metrics indicate ongoing academic visibility within pharmaceutical and pharmacognosy-related research communities.[1][5]

Award Suitability

Naglaa Shehab demonstrates suitability for recognition within pharmaceutical and biomedical academic platforms due to her contributions to drug discovery, pharmacognosy, medicinal plant investigations, and pharmaceutical sciences education. Her participation in scientific publishing, interdisciplinary collaborations, and research development aligns with the objectives of international pharmaceutical recognition initiatives. The combination of research productivity, editorial engagement, and pharmaceutical innovation supports her relevance to academic award and editorial board recognition programs.[5]

Conclusion

The academic profile of Naglaa Shehab reflects continued engagement in pharmaceutical sciences, medicinal plant investigations, and natural product research. Her scholarly contributions encompass pharmaceutical formulations, phytochemical analysis, biological evaluation, and interdisciplinary healthcare applications. Through editorial participation, scientific publications, and pharmaceutical research activities, she contributes to ongoing developments within drug discovery and pharmaceutical innovation.[1][2]

References

  1. ORCID. (2026). Naglaa Shehab ORCID profile and academic activities. ORCID Registry.https://orcid.org/0000-0002-7514-4055
  2. Elsevier. (n.d.). Scopus author details: Naglaa Shehab, Author ID 26424069600. Scopus.https://www.scopus.com/authid/detail.uri?authorId=26424069600
  3. Khalifa, A., Shehab, N.G., et al. (2026). Development of Phyllanthus emblica Extract-Loaded Niosomes for Cancer Treatment: Formulation and In Vitro Evaluation. Pharmaceuticals.DOI:https://doi.org/10.3390/ph19040582
  4. Bou Malhab, L.J., Shehab, N.G., et al. (2023). Potential Anticancer Properties of Calotropis procera: An Investigation on Breast and Colon Cancer Cells. Heliyon.DOI:https://doi.org/10.1016/j.heliyon.2023.e16706
  5. Anbar, H.S., El Wakil, A., Shehab, N.G., et al. (2024). The wound healing and hypoglycemic activates of date palm (Phoenix dactylifera) leaf extract and saponins in diabetic and normal rats. PLOS ONE.
    DOI: https://doi.org/10.1371/journal.pone.0308879

Mr. Yeniewa Anagaw| Pharmacy|Best Researcher Award

Published on by Top Pharmaceutical

Mr. Yeniewa Anagaw| Pharmaceutical Pharmacy
|Best Researcher Award

Mr. Yeniewa Anagaw at Medical University of Gondar,Ethiopia

PROFILE  

scopus

Google scholar

Early Academic Pursuits 📚

Yeniewa Kerie Anagaw’s journey in academia began with his Bachelor of Pharmacy degree from Miza-Tepi University, Ethiopia, in 2016. Graduating with a commendable cGPA of 3.39/4.00, his directed study explored a critical area of public health, specifically focusing on tuberculosis treatment outcomes and predictors among HIV patients in Southwest Ethiopia. This early research demonstrated his keen interest in addressing significant health challenges affecting his community. He continued his academic growth with a Master of Science in Pharmaceutical Analysis and Quality Assurance at Addis Ababa University, where he earned an impressive cGPA of 3.81/4.00. His thesis, titled “Analytical Method Development and Validation Based on Paper Analytical Device (PAD) for Adulteration Detection in Teff Injera (Ethiopian flatbread),” highlights his dedication to innovation in pharmaceutical analysis and public health. This work, which employed Microwave Plasma Atomic Emission Spectroscopy (MP-AES), underscores his analytical and scientific rigor.

Professional Endeavors and Teaching Commitments 👨‍🏫

Yeniewa’s professional career took off in December 2016 when he joined Finote Selam General Hospital as a junior pharmacist. In this role, he participated in ward rounds and patient chart reviews, where he helped identify, prevent, and mitigate drug-related problems. His responsibilities included ensuring appropriate drug selection and dosage, managing adverse drug reactions, addressing drug interactions, and preparing compounded dermatological formulations. Yeniewa also worked as a pharmacy coordinator, showcasing his leadership and organizational skills early in his career.

By January 2018, Yeniewa transitioned into academia as an assistant lecturer at the University of Gondar’s School of Pharmacy. In this role, he supervised and instructed undergraduate students in Pharmaceutical Analysis laboratory sessions, focusing on hands-on training in instrumental analysis and data interpretation. His role expanded to delivering lectures in Pharmaceutical Analysis, Pharmacy Practice, and Quality Control and Assurance. Yeniewa’s dynamic teaching style, coupled with his passion for research, has made him a pivotal figure in shaping future pharmacists.

Since April 2022, Yeniewa has held a lecturer position at the University of Gondar. Here, his responsibilities have evolved to include not only lecture preparation and delivery but also student mentoring, exam evaluation, and practical learning experiences. Yeniewa’s teaching covers Electroanalytical Methods, IR Spectroscopy, NMR, HPLC, and Mass Spectrometry (MS), which are crucial tools in the field of pharmaceutical science. His ability to guide students through both theoretical and practical knowledge demonstrates his comprehensive approach to education.

Contributions and Research Focus 🔬

Yeniewa’s research interests span across various domains within pharmaceutical sciences, including pharmaceutical analysis, quality assurance, proteomics, metabolomics, drug delivery, and biomarker discovery. His dedication to research is reflected in his published works and his involvement in grant writing for school projects. Yeniewa is particularly passionate about developing analytical methods for drug adulteration detection, exemplified by his thesis on detecting adulterants in Teff Injera. This research is crucial for ensuring food safety and protecting public health.

Additionally, Yeniewa has participated in several community service initiatives. One notable contribution involved the quantitative analysis of table salt used for wound cleaning, showcasing his commitment to improving healthcare practices in Ethiopia. His engagement in such community-oriented projects demonstrates his desire to translate academic research into practical solutions that benefit society.

Accolades and Recognition 🏅

Throughout his career, Yeniewa has earned various certificates and recognition for his contributions to both academia and the pharmaceutical field. Some of his notable achievements include:

  • Certificate of the training workshop on “Anticancer Medicines Quality Evaluation Using the Chemo-spot System.”
  • BMJ Open Reviewer’s Certificate and Peer Reviewer Verification Certificates from Springer Nature, which highlight his contributions to scientific literature through peer review.
  • Presenter Certificate at the “42nd Annual Scientific Conference of the Ethiopia Pharmacy Association (EPA),” where he shared his research with a broader scientific community.
  • Certificates for attending workshops and training sessions on research enhancement, intellectual property, and good manufacturing practices (GMP), indicating his commitment to continuous professional development.

Impact and Influence 🌍

Yeniewa’s influence extends beyond his immediate academic and professional circles. His research on tuberculosis treatment and pharmaceutical adulteration contributes to public health advancements, particularly in Ethiopia. By addressing key issues in drug safety and treatment optimization, he has played a role in enhancing healthcare outcomes for vulnerable populations. As a lecturer, Yeniewa has directly impacted the education of future pharmacists, providing them with the knowledge and skills necessary to excel in both clinical and research settings. His involvement in grant writing and school projects also demonstrates his efforts to foster research initiatives that could have far-reaching benefits.

Legacy and Future Contributions 🌟

As Yeniewa continues his career, his focus remains on bridging the gap between pharmaceutical research and practical healthcare solutions. His expertise in proteomics, drug discovery, and spectroscopic methods positions him as a valuable contributor to ongoing efforts in pharmaceutical innovation. Furthermore, his dedication to teaching ensures that future generations of pharmacists are well-equipped to tackle emerging challenges in the field.

Yeniewa’s future contributions are likely to leave a lasting legacy, both in terms of academic excellence and practical healthcare improvements. His adaptability, hard work, and passion for both teaching and research will continue to drive his success as he navigates the evolving landscape of pharmaceutical sciences.

🎓Publication 

Outcome of tuberculosis treatment and its predictors among HIV infected patients in southwest Ethiopia

  • Authors   :Adane Teshome Kefale, Yeniewa Kerie Anagaw
  • Journal    :International Journal of General Medicine
  • Year         :2017

Assessment of community pharmacy professionals’ willingness, involvement, beliefs, and barriers to offer health promotion services: a cross-sectional study

  • Authors   : Wondim Ayenew, Abdulwase Mohammed Seid, Asmamaw Emagn Kasahun, Asrat Elias Ergena, Derso Teju Geremaw, Liknaw Workie Limenh, Teshome Bitew Demelash, Wudneh Simegn, Yeniewa Kerie Anagaw, L.
  • Journal    :BMC Health Services Research
  • Year         :2022

Assessment of Knowledge, Attitudes, and Practices of Traditional Healers toward Dosage Forms and Routes of Administration: A Cross‐Sectional Study in Ethiopia

  • Authors   : Liknaw Workie Limenh, Derso Teju Geremew, Asmamaw Emagn Kasahun, Yeniewa Kerie Anagaw, Minichil Chanie Worku, Wudneh Simegn, Wondim Ayenew
  • Journal    :Evidence‐Based Complementary and Alternative Medicine
  • Year         :2023

Assessment of knowledge, attitude, and practice on substandard and counterfeit pharmaceutical products among pharmacy professionals in Gondar City, North-West Ethiopia

  • Authors   :Minichil Chanie Worku, Melese Legesse Mitku, Wondm Ayenew, Liknew Workie Limenh, Asrat Elias Ergena, Derso Teju Geremew, Gizachew Kassahun Bizuneh, Bereket Bahiru Tefera, Biset Asrade Mekonnen, Yeniewa Kerie Anagaw
  • Journal    :Currents in Pharmacy Teaching and Learning
  • Year         :2024

Prevalence and predictors of self-medication with antibiotics in Ethiopia: a systematic review and meta-analysis

  • Authors   :Wondim Ayenew, Tewodros Ayalew Tessema, Yeniewa Kerie Anagaw, Ebrahim Abdela Siraj, Segenet Zewdie, Wudneh Simegn, Liknaw Workie Limenh, Chernet Tafere, Ashagrachew Tewabe Yayehrad
  • Journal    :Antimicrobial Resistance & Infection Control
  • Year         :2024

Prof. Fatma YURT|pharmaceuticals | Best Researcher Award

Published on by Top Pharmaceutical

Prof. Fatma YURT |pharmaceuticals|Best Researcher Award|

Prof. Fatma YURT atEge University,Turkey

PROFILE  

scopus

Orcid

Early Academic Pursuits 🎓

Prof. Dr. Fatma Yurt’s journey into the scientific world began at Ege University, one of Turkey’s leading institutions. She completed her undergraduate studies at the Faculty of Science in the Department of Chemistry between 1982 and 1987. Her passion for science and dedication to learning set the stage for her illustrious career in nuclear sciences. Following her bachelor’s degree, she pursued a doctorate at Ege University in the Institute of Nuclear Sciences, specializing in Nuclear Sciences. From 1991 to 1998, she immersed herself in the study of nuclear applications, gaining a deep understanding of the field’s complexities and potential. This period of intense academic focus and research laid a solid foundation for her future contributions to nuclear medicine, radiopharmacy, and related fields.

Professional Endeavors 💼

Prof. Dr. Fatma Yurt’s professional career is marked by her steady rise through the academic ranks at Ege University. She began her career as a Research Assistant in the Nuclear Applications Department of the Institute of Nuclear Sciences, where she served from 1994 to 1997. This role allowed her to engage in cutting-edge research and contribute to the development of nuclear sciences in Turkey.

In 1999, she was promoted to Assistant Professor, and later in the same year, she achieved the rank of Associate Professor. Her commitment to education and research was evident as she continued to mentor students and lead research projects in nuclear applications. By 2007, she had earned the title of Professor, solidifying her position as a leading expert in her field.

Prof. Dr. Yurt’s expertise is not limited to academia; she has also held significant administrative roles. Since 2016, she has served as the Director of the Institute of Nuclear Sciences at Ege University. In this capacity, she has been instrumental in shaping the direction of nuclear research and education in Turkey, overseeing various projects and initiatives that have expanded the institute’s influence both nationally and internationally.

Contributions and Research Focus 🔬

Prof. Dr. Fatma Yurt’s research spans several critical areas within nuclear sciences, with a particular emphasis on nuclear medicine, radiopharmacy, and pharmacology. Her work in these fields has been pivotal in advancing the understanding and application of nuclear techniques in medicine, particularly in diagnosing and treating various diseases.

Her research contributions include the development of novel radiopharmaceuticals, which are essential for diagnosing and treating conditions such as cancer. Prof. Dr. Yurt’s expertise in nuclear chemistry and physical chemistry has enabled her to explore the intricate processes involved in the synthesis and application of these compounds. She has also contributed significantly to the field of health sciences, particularly in the areas of internal medicine and pharmaceutical technology.

With a Scopus publication count of 123 and a Unisis publication count of 296, Prof. Dr. Yurt’s research output is impressive. Her work has been cited over 1,447 times on Scopus, reflecting the impact and relevance of her research. Her H-Index, a measure of both the productivity and citation impact of her publications, stands at 21 on Scopus, further underscoring her influence in the field.

Accolades and Recognition 🏆

Throughout her career, Prof. Dr. Fatma Yurt has received numerous accolades and recognition for her contributions to nuclear sciences and medicine. Her research has been widely acknowledged by her peers, and she has been invited to present her findings at various national and international conferences. Her role as the Director of the Institute of Nuclear Sciences is a testament to her leadership abilities and her dedication to advancing the field of nuclear applications.

Prof. Dr. Yurt’s work has not only advanced scientific understanding but has also had a tangible impact on healthcare. Her contributions to radiopharmacy have been particularly significant, with her research playing a crucial role in the development of new diagnostic and therapeutic methods. Her dedication to her field is further demonstrated by her ongoing involvement in academic mentorship, helping to train the next generation of scientists in nuclear sciences.

Impact and Influence 🌍

Prof. Dr. Yurt’s influence extends beyond her research and academic roles. As a leader in nuclear sciences, she has been instrumental in promoting the importance of nuclear applications in medicine and other fields. Her work has helped to bridge the gap between basic research and practical applications, ensuring that the benefits of nuclear science are realized in clinical settings.

Her leadership at the Institute of Nuclear Sciences has also been pivotal in shaping the research agenda in Turkey, encouraging interdisciplinary collaboration and fostering a culture of innovation. Under her guidance, the institute has strengthened its position as a center of excellence in nuclear research, attracting students and researchers from around the world.

Legacy and Future Contributions 🌟

Prof. Dr. Fatma Yurt’s legacy is one of dedication, innovation, and leadership. Her contributions to nuclear medicine, radiopharmacy, and related fields have had a lasting impact on both the scientific community and the broader healthcare sector. As she continues her work, her influence will undoubtedly grow, inspiring new research and leading to further advancements in nuclear applications.

🎓Publication 

An in vitro evaluation of Hypericum perforatum loaded-chitosan nanoparticle/agarose film as a Wound dressing

Unveiling combat strategies against Candida spp. biofilm structures: Demonstration of photodynamic inactivation with innovative phthalocyanine derivatives

Platinum (II) Schiff Base Complexes and their Effects on the Inhibition of Amyloid β1–42 Aggregation

In Vitro Assessment of 177Lu-Labeled Trastuzumab-Targeted Mesoporous Carbon@Silica Nanostructure for the Treatment of HER2-Positive Breast Cancer

  • Authors   :Tunçel, A., Maschauer, S., Prante, O., Yurt, F.
  • Journal    :Pharmaceuticals
  • Year         :2024